Eagle Pharma rapidly infused admix equivalent to Treanda

• In a Phase 1 trial, Eagle Pharmaceuticals' (NASDAQ:EGRX +2.2%) 50 ml admixture of bendamustine hydrochloride delivered via 10-minute rapid infusion was equivalent to an admixture of 500 ml of Treanda (bendamustine HCL) delivered via 60-minute infusion. The study met its primary endpoint of bioequivalence.
• A more rapidly infused product would be beneficial to cancer patients.
• The FDA issued tentative approval for the low volume infusion in July 2014. It designated it an Orphan Drug for chronic lymphocytic leukemia and indolent B-cell non-Hodgkins lymphoma on July 2, 2014.